Phase II study of lonidamine and diazepam in the treatment of recurrent glioblastoma multiforme

Journal of Neuro-Oncology

Volumn 63, Issue 1, 2003, Pages 81-86

  Oudard, Stéphane ^a   Carpentier, Antoine ^b   Banu, Eugeniu ^a   Fauchon, François ^c   Celerier, Denis ^d   Poupon, Marie F ^e   Dutrillaux, Bernard ^e   Andrieu, Jean M ^a   Delattre, Jean Y ^b  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^c Department of Radiotherapy   (France)

^d Dept of Onco Radiotherapy ^*  (France)

^e CNRS   (France)

Author keywords

Diazepam; Glioblastoma; Lonidamine

Indexed keywords

ALKYLATING AGENT; ANTINEOPLASTIC AGENT; CARMUSTINE; CISPLATIN; CORTICOSTEROID; DIAZEPAM; FOTEMUSTINE; LONIDAMINE; NITROSOUREA;

ADULT; AGED; ARTICLE; ASTHENIA; BLOOD TOXICITY; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CYTOSTASIS; DISEASE DURATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FATALITY; DRUG TARGETING; DRUG TOLERABILITY; ENERGY METABOLISM; FEMALE; GLIOBLASTOMA; HUMAN; MALE; MITOCHONDRION; MULTICENTER STUDY; MULTIMODALITY CANCER THERAPY; MYALGIA; NEUROSURGERY; OPEN STUDY; PAIN; PHASE 2 CLINICAL TRIAL; PROGNOSIS; RECURRENT CANCER; SOMNOLENCE; TESTIS DISEASE;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DIAZEPAM; FEMALE; GLIOBLASTOMA; HUMANS; INDAZOLES; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; SURVIVAL RATE;

EID: 0038206442     PISSN: 0167594X     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1023756707900     Document Type: Article

References (19)

1. Delattre JY, Uchuya M: Radiotherapy and chemotherapy for gliomas. Curr Opin Oncol 8: 196-203, 1996
2. Warburg O: On the origin of cancer cells. Science 123: 309-314, 1956
3. Nakashima RA, Mangan PS, Colombini M, Pedersen PL: Hexokinase receptor complex in hepatoma mitochondria: Evidence from N,N′-dicyclohexylcarbodiimide-labelling studies for the involvement of the pore-forming protein VDAC. Biochemistry 25: 1015-1021, 1986
4. Oudard S, Arvelo F, Miccoli L, Apiou F, Dutrillaux AM, Poisson M, Dutrillaux B, Poupon MF: High glycolysis in gliomas despite low hexokinase transcription and activity correlated to chromosome 10 loss. Br J Cancer 74: 839-845, 1996
5. Bigner SH, Mark J, Bigner DD: Cytogenetics of human brain tumours. Cancer Genet Cytogenet 47: 141-154, 1990
6. Linden M, Gellerfors P, Nelson BD: Pore protein and the hexokinase-binding protein from the outer membrane of rat liver mitochondria are identical. FEBS Lett 14: 189-192, 1982
7. Miettinen H, Kononen J, Haapasalo H, Helen P, Sallinen P, Harjuntausta T, Helin H, Alho H: Expression of peripheral-type benzodiazepine receptor and diazepam-binding inhibitor in human astrocytomas: Relationship to cell proliferation. Cancer Res 55: 2691-2695, 1995
8. Wang JKT, Morgan JI, Spector S: Differentiation of Friend erythroleukemia cells induced by benzodiazepines. Proc Natl Acad Sci USA 81: 3770-3772, 1984
9. Wang JKT, Morgan JI, Spector S: Benzodiazepines that bind at peripheral sites inhibits cell proliferation. Proc Natl Acad Sci USA 81: 753-756, 1984
10. Carayon P, Portier M, Dussossoy D, Bord A, Petitpretre G, Canat X, Le Fur G, Casellas P: Involvement of peripheral benzodiazepine receptors in the protection of haematopoietic cells against oxygen radical damage. Blood 87: 3170-3178, 1996
11. Miccoli L, Poirson-Bichat F, Sureau F, Bras Goncalves R, Bourgeois Y, Dutrillaux B, Poupon MF, Oudard S: Potentiation of lonidamine and diazepam, two agents acting on mitochondria, in human glioblastoma treatment. J Natl Cancer Inst 18: 1400-1406, 1998
12. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, Silvestrini B, Caputo A: Effect of lonidamine on the energy metabolism of Ehrlich ascites tumour cells. Cancer Res 41: 4661-4666, 1981
13. Oudard S, Poirson F, Miccoli L, Bourgeois Y, Vassault A, Poisson M, Magdelenat H, Dutrillaux B, Poupon MF: Mitochondria-bound hexokinase as target for therapy of malignant gliomas. Int J Cancer 62: 216-222, 1995
14. Carapella CM, Paggi MG, Cattani F, Ciottoli GB, Floridi A, Iandolo B, Raus L, Riccio A, Caputo A: The potential role of lonidamine in the treatment of malignant gliomas; a phase II study. J Neuro-Oncol 7: 103-108, 1989
15. Braestrup C, Squires RF: Specific benzodiazepine receptors in rat brain characterized by high-affinity [3H]diazepam binding. Proc Natl Acad Sci USA 74: 3805-3809, 1997
16. Floridi A, Lehninger AL: Action of the antitumour and antispermatogenic agent lonidamine on electron transport in Ehrlich ascites tumor mitochondria. Arch Biochem Biophys 226: 73-83, 1983
17. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, Petit PX, Hirsch F, Goulbern M, Poupon MF, Miccoli L, Xie Z, Reed JC, Kroemer G: Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permiability transition pore. Oncogene 18: 2537-2546, 1999
18. Beurdeley-Thomas A, Miccoli L, Oudard S, Dutrillaux B, Poupon MF: The peripheral benzodiazepine receptors: A review. J Neuro-Oncol 46: 45-56, 2000
19. Carapella CM, Paggi MG, Calvosa F, Cattani F, Jandolo B, Mastrostefano R, Raus L, Riccio A: Lonidamine in the combined treatment of malignant gliomas. J Neurosurg Sci 34: 261-264, 1990